

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,  
INC. and AKORN INC.,<sup>1</sup>  
Petitioners,

v.

ALLERGAN, INC.  
Patent Owner.

---

Case IPR2016-01127 (US 8,685,930 B2)  
Case IPR2016-01128 (US 8,629,111 B2)  
Case IPR2016-01129 (US 8,624,556 B2)  
Case IPR2016-01130 (US 8,633,162 B2)  
Case IPR2016-01131 (US 8,648,048 B2)  
Case IPR2016-01132 (US 9,248,191 B2)

---

**PETITIONER'S NOTICE OF DEPOSITION OF  
RHETT M. SCHIFFMAN, M.D.**

---

<sup>1</sup> Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599, IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601, have respectively been joined with the captioned proceedings. The word-for-word identical paper is filed in each proceeding identified in the caption pursuant to the Board's Scheduling Order (Paper 10).

Pursuant to 37 C.F.R. § 42.53, Petitioner Mylan Pharmaceuticals Inc., by and through its attorneys, will conduct examination by deposition of Rhett M. Schiffman, M.D. Dr. Schiffman's deposition will take place commencing at 9:00AM (local time) on June 1, 2017, continuing day-to-day if necessary, at the offices of Gibson Dunn & Crutcher LLP, 3161 Michelson Dr., Irvine, CA 92612, or at another location mutually agreeable to the parties. The deposition will be taken before a Notary Public or other officer authorized by law to administer oaths and will be recorded using stenographic means. The arrangement for the reporter will be made by counsel for Petitioner. Petitioner expressly reserves the right to continue the deposition of Dr. Schiffman after Patent Owner has complied with Petitioner's discovery requests, as indicated by the Board during the parties' May 15, 2017 conference call with the Board.

Respectfully submitted,

Dated: May 22, 2017

/ Steven W. Parmelee /

Steven W. Parmelee

Reg. No. 31,990

## CERTIFICATE OF SERVICE

This is to certify that I caused to be served a true and correct copy of the foregoing Petitioner's Notice of Deposition of Rhett M. Schiffman, M.D., on this 22nd day of May, 2017, on the Patent Owner at the correspondence address of the Patent Owner as follows:

Dorothy P. Whelan  
Michael Kane  
Susan Morrison Colletti  
Robert M. Oakes  
Fish & Richardson P.C.  
3200 RBC Plaza  
60 South Sixth Street  
Minneapolis, MN 55402  
Email: [IPR13351-0008IP1@fr.com](mailto:IPR13351-0008IP1@fr.com)  
Email: [IPR13351-0008IP2@fr.com](mailto:IPR13351-0008IP2@fr.com)  
Email: [IPR13351-0008IP3@fr.com](mailto:IPR13351-0008IP3@fr.com)  
Email: [IPR13351-0008IP4@fr.com](mailto:IPR13351-0008IP4@fr.com)  
Email: [IPR13351-0008IP5@fr.com](mailto:IPR13351-0008IP5@fr.com)  
Email: [IPR13351-0008IP6@fr.com](mailto:IPR13351-0008IP6@fr.com)  
Email: [PTABInbound@fr.com](mailto:PTABInbound@fr.com)

and on the remaining petitioners as follows:

Gary Speier  
Mark Schuman  
CARLSON, CASPERS, VANDENBURGH,  
LINDQUIST & SCHUMAN, P.A.  
225 South Sixth Street, Suite 4200  
Minneapolis, MN 55402  
Email: [gspeier@carlsoncaspers.com](mailto:gspeier@carlsoncaspers.com)  
Email: [mschuman@carlsoncaspers.com](mailto:mschuman@carlsoncaspers.com)  
*Attorneys for Teva Pharmaceuticals USA, Inc.*

Michael Dzwonczyk  
Azadeh Kokabi  
Travis Ribar  
SUGHRUE MION, PLLC  
2100 Pennsylvania Ave., NW  
Washington, DC 20037  
Email: [mdzwonczyk@sughrue.com](mailto:mdzwonczyk@sughrue.com)  
Email: [akokabi@sughrue.com](mailto:akokabi@sughrue.com)  
Email: [tribar@sughrue.com](mailto:tribar@sughrue.com)  
*Attorneys for Akorn Inc.*

Respectfully submitted,

Dated: May 22, 2017

/ Steven W. Parmelee /  
\_\_\_\_\_  
Steven W. Parmelee, Lead Counsel  
Reg. No. 31,990